BioVie reports topline Phase 2 SUNRISE-PD results for bezisterim in early Parkinson's disease
The company said its trial met prespecified endpoints, with bezisterim showing statistically significant benefits on inflammatory, motor, and non-motor measures versus placebo.
SEC filing